Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus–Related Head and Neck Cancer

Spanos, William C.; Nowicki, Paul N; Lee, Dong Hoon; Hoover, A.; Hostager, Bruce S.; Gupta, Anjali; Anderson, Mary E.; Lee, John H.

doi:10.1001/archoto.2009.159

Cited by 227 publications

(231 citation statements)

References 28 publications

Supporting

Mentioning

217

Contrasting

Unclassified

Order By: Relevance

“…Increased MHC class I expression upon irradiation could in part explain why HPV-positive tumors with absent/low MHC class I expression still respond readily to therapy and are recognized by the immune system (91). Eliciting a vigorous immune response in this context, would be in line with data obtained in mice, where HPV-positive tumors were curable after cisplatin or radiation therapy only in immunocompetent and not in immunoincompetent mice (92). In that system, it was proposed that being able to mount an immune response was required to eradicate these tumors (92).…”

Section: Studies Focusing On Immunological and Stem Cell Markers In Tsupporting

confidence: 60%

“…Eliciting a vigorous immune response in this context, would be in line with data obtained in mice, where HPV-positive tumors were curable after cisplatin or radiation therapy only in immunocompetent and not in immunoincompetent mice (92). In that system, it was proposed that being able to mount an immune response was required to eradicate these tumors (92).…”

Section: Studies Focusing On Immunological and Stem Cell Markers In Tsupporting

confidence: 59%

See 1 more Smart Citation

Human Papillomavirus and Potentially Relevant Biomarkers in Tonsillar and Base of Tongue Squamous Cell Carcinoma

Näsman

Bersani

Lindquist

et al. 2017

View full text Add to dashboard Cite

Abstract. Human papillomavirus (HPV)-positive tonsillarand base of tongue cancer is increasing epidemically and has much better outcome than corresponding HPV-negativeIn 2007, human papillomavirus (HPV) was recognized as a risk factor for oropharyngeal squamous cell carcinoma (OPSCC) by the International Agency for Research against Cancer (IARC), besides the traditional risk factors smoking and alcohol (1-4). Concurrently, an increased incidence of OPSCC, more specifically tonsillar and base of tongue cancer (TSCC and BOTSCC, the two main HPV-positive OPSCC sites) was described in many developed countries, and found to be due to a sharp rise of HPV-positive cases (5-18). These HPV-positive tumors had a much better clinical outcome than their HPV-negative counterparts and head and neck squamous cell carcinoma (HNSCC) in general when treated with radiotherapy and surgery (1-3, 15-17, 19, 20). Treatment of HNSCC including OPSCC has, however, gradually become more intensified with induction chemotherapy or concurrent chemo-radiotherapy and sometimes the administration of Erbitux, leading to more severe side effects (16, 20, 21). This is likely unnecessary for most HPV-positive TSCC and BOTSCC patients since they generally respond well to less therapy and furthermore, intensified therapy does not improve survival of [15][16][17] 20, 22, 23). It is, therefore, important to identify patients with HPV-positive TSCC and BOTSCC eligible for less treatment or targeted therapy and efforts focus now on finding predictive and targetable markers for these patients (24-39).Here, a short background of the field and an update on recent attempts to find predictive and targetable markers with different methodologies for individualized therapy is presented. Human Papillomavirus in Tonsillar and Base of Tongue Squamous Cell Carcinoma and an Epidemic Increase of these TumorsIn 2000, an association between HPV and OPSCC and TSCC was reported, and with radiotherapy and surgery, these HPVpositive cases had much better outcome than corresponding HPV-negative cases (80% vs. 40-50% 5-year survival) (1, 2). In 2004, a similar relationship of HPV to BOTSCC, but not to mobile tongue cancer was disclosed (40). Based on 5319

show abstract

Section: Studies Focusing On Immunological and Stem Cell Markers In Tsupporting

confidence: 60%

Section: Studies Focusing On Immunological and Stem Cell Markers In Tsupporting

confidence: 59%

Human Papillomavirus and Potentially Relevant Biomarkers in Tonsillar and Base of Tongue Squamous Cell Carcinoma

Näsman

Bersani

Lindquist

et al. 2017

View full text Add to dashboard Cite

show abstract

“…30 Cisplatinbased therapy results in tumor clearance in wild type but not in Rag 1 mice. 31 Two studies have shown that the proportion of T cells that are specific for HPV16 E7 peptides among CD8þ T cell is significantly increased (three to fourfold) in PBMC of patients with HPV-positive oropharyngeal cancer when compared with HPV-negative patients. 13,32 More recently, a flow cytometry analysis of peripheral blood samples of patients with OSCC before treatment showed that HPV-positive patients have an increased number of 33 found no significant difference in TIL infiltrates among HPVpositive and HPV-negative patients.…”

Section: Discussionmentioning

confidence: 99%

CD8‐alpha T‐cell infiltration in human papillomavirus‐related oropharyngeal carcinoma correlates with improved patient prognosis

Jung

Guihard²,

Krugell³

et al. 2012

Intl Journal of Cancer

View full text Add to dashboard Cite

Patients with human papillomavirus (HPV)-related oropharyngeal tumors display improved prognosis. The biological basis of this tumor phenotype is poorly understood. We investigated whether increased lymphocyte infiltrate in HPV-positive oropharyngeal squamous cell carcinomas could account for better prognosis. We previously identified, in an Affymetrix GeneChip analysis of 83 HPV-unrelated and 11 HPV-related squamous cell carcinoma of the oropharynx, several candidate genes, including CD8a and CD3f. Their expression was validated in this study by qRT-PCR on an independent clinical series of 144 oropharyngeal tumors. Immunohistochemical staining of tumor specimens was performed to evaluate infiltration of tumor stroma by CD81 and CD41 lymphocytes. The prognostic value of CD8a and CD3f expression levels was measured by Kaplan-Meier and Cox regression model analyses. Immune response-related signaling pathways were found to be deregulated in HPV-positive oropharyngeal tumors. Expression of CD8a, CD3f, granzyme K, CD28 and integrin aL RNAs was upregulated in HPV-positive lesions when compared with HPV-unrelated tumors (p < 0.05). Stroma of HPV-positive tumors was frequently and strongly infiltrated by CD8a-and CD3f-positive T cells. CD8a RNA expression correlated with both improved global (Kaplan-Meier; p 5 0.005; Cox regression: p 5 0.003) and disease-free (Cox regression: p 5 0.04) survival. CD3f RNA expression correlated with improved overall survival (Cox regression: p 5 0.024). These results suggest that an increased cytotoxic T-cell-based antitumor immune response is involved in improved prognosis of patients with HPV-positive tumors.The presence of human papillomaviruses (HPVs; mainly HPV type 16) correlates with the onset and development of about 25% of head and neck squamous cell carcinomas (HNSCC). 1 HPV-positive cancers of the head and neck arise mainly in the oropharynx and define a subgroup of radioand chemosensitive tumors with distinct clinical, pathological and molecular features and improved prognosis with respect to their HPV-negative counterparts. [2][3][4][5] The majority of HPVrelated oropharyngeal squamous cell carcinomas (OSCC) express wild-type TP53, 6,7 which might be involved in the improved response of tumors to treatment. Despite thorough analysis of gene expression profiles of HPV-positive OSCC by several groups, [8][9][10][11] no novel prognostic or predictive biomarker has been identified, and the molecular mechanisms that underlie improved prognosis of HPV-related OSCC are poorly understood.The immune response has an important impact in many HPV-associated tumors and can have either favorable or unfavorable consequences. 12 The importance of the immune response in HPV-related OSCC is less well established. An increased T-cell response against HPV E7 epitopes has been detected in the blood of patients with HPV-positive HNSCC. 13-15 A more recent study has shown that T cells that proliferate and synthesize inflammatory cytokines upon HPV16 E6 and E7 oncoprotein recognition can be isolate...

show abstract

“…Также есть данные, что опухолевым и иммунным взаи-модействием объясняется лучший ответ ВПЧ-пози-тивных опухолей. ВПЧ-позитивность ассоциирована с лимфоцитарным ответом, а на животных моделях показано, что иммунокомпетентность -это необхо-димое условие для полного лизиса опухоли [26,33].…”

Section: возможности таргетной терапии при мутациях онкогеновunclassified

Treatment of Head and Neck Squamous Cell Carcinoma According on the Specific Molecular Features of the Tumor (A Literature Review)

Stukan¹,

Murashko²,

Бодня³

et al. 2017

Opuholi golovy šei

View full text Add to dashboard Cite

Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus–Related Head and Neck Cancer

Cited by 227 publications

References 28 publications

Human Papillomavirus and Potentially Relevant Biomarkers in Tonsillar and Base of Tongue Squamous Cell Carcinoma

Human Papillomavirus and Potentially Relevant Biomarkers in Tonsillar and Base of Tongue Squamous Cell Carcinoma

CD8‐alpha T‐cell infiltration in human papillomavirus‐related oropharyngeal carcinoma correlates with improved patient prognosis

Treatment of Head and Neck Squamous Cell Carcinoma According on the Specific Molecular Features of the Tumor (A Literature Review)

Contact Info

Product

Resources

About